References
- Boehringer Ingelheim Pharmaceuticals, Inc. Highlights of prescribing information. Spiriva® HandiHaler® (tiotropium bromide inhalation powder), for oral inhalation use. U.S. FDA Revised 2/2018; 2018; [cited 2018 Mar 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021395s048lbl.pdf
- Boehringer Ingelheim International GmbH. Summary of product characteristics. Spiriva 18 microgram inhalation powder, hard capsule. Europe: MHRA Revised 10/2016; 2016; [cited 2018 Mar 26]. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1520572472405.pdf
- Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013:CD009552.
- Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management, and prevention: a guide for health care professionals; 2017; [cited 2018 Feb 23]. Available from: http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf
- Rice KL, Kunisaki KM, Niewoehner DE. Role of tiotropium in the treatment of COPD. Int J Chron Obst Pulmon Dis. 2007;2(2):95–105.
- Dougall S, Bolt J, Semchuk W, et al. Inhaler assessment in COPD patients: a primer for pharmacists. Can Pharm J. 2016;149(5):268–273.
- Rootmensen GN, Van Keimpema AR, Jansen HM, et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010;23(5):323–328.
- Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333.
- Center for Drug Evaluation and Research. Application number 21-395: clinical pharmacology and biopharmaceutics review(s); 2001; [cited 2018 Feb 23]. Available from: http://www.fda.gov
- Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence; 2010; [cited 2018 Feb 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
- Vetchý D, Frýbortová K, Rabisková M, et al. Bioequivalence studies of pharmaceutical preparations. Cas Lek Cesk. 2007;146(5):431–433.
- United States Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation: draft guidance; 2013; [cited 2018 Mar 26]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf
- European Medicines Agency. Guideline on bioanalytical method validation: draft guidance; 2011; [cited 2018 Mar 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: clinical safety data management: definitions and standards for expedited reporting: E2A; 1994; [cited 2018 Feb 23]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf
- Hohlfeld JM, Sharma A, Van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–414.
- Beeh KM, Kirsten AM, Dusser D, et al. Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium Respimat® in asthma using standardized sample-contamination avoidance. J Aerosol Med Pulm Drug Deliv. 2016;29(5):406–415.
- Chi J, Li F, Jenkins R. Ultrasensitive sub-pg/ml determination of tiotropium bromide in human plasma by 2D-UHPLC–MS/MS: challenges and solutions. Bioanalysis. 2016;8(5):385.
- Wang J, Jiang Y, Wang Y, et al. Highly sensitive assay for tiotropium, a quaternary ammonium, in human plasma by high‐performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(11):1755–1758.
- Algorta J, Andrade L, Medina M, et al. Pharmacokinetic bioequivalence of two inhaled tiotropium bromide formulations in healthy volunteers. Clin Drug Investig. 2016;36(9):753.
- Borgstrom L, Bengtsson T, Derom E, et al. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler®. Int J Pharm. 2000;193(2):227–230.